A Study of Olaratumab Alone and in Combination With Standard Chemotherapy in Children With Cancer

Registry ID

EUCTR2015-005721-39

Source registry

EUCTR

Phase

PHASE1

Sponsor

Eli Lilly and Company

Last update

2026-08-16

Conditions

• Neoplasm Metastasis

Summary

Determine a recommended dose of olaratumab in combination with at least one of the studied chemotherapy regimens in pediatric patients based on any dose-limiting toxicities (DLTs) as well as olaratumab serum exposure-matching between the adult and pediatric populations

Related clinical trials

• PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
• A Study of LY4257496 in Participants With Cancer (OMNIRAY)
• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
• A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
• A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

View on source registry